Immix Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Immix Biopharma, Inc. (IMMX) on July 17, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. The report addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Accountant Change: On July 17, 2024, the Company dismissed KMJ Corbin & Company LLP ("KMJ") as its independent registered public accounting firm.
- New Appointment: Crowe LLP ("Crowe") was appointed as the new independent registered public accounting firm, effective July 17, 2024.
- Reason for Change: The transition occurred because the partners and professional staff of KMJ joined Crowe LLP on May 20, 2024.
- Audit History: KMJ's reports for the fiscal years ended December 31, 2023, and 2022 contained no adverse opinions, disclaimers, or qualifications.
- Disagreements: There were no disagreements between the Company and KMJ regarding accounting principles, practices, or audit scope during the two most recent fiscal years or the subsequent interim period.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management outlook, or specific risk factors beyond the standard disclosure of the auditor change. The Company confirmed that no "reportable events" occurred during the tenure of the former auditor. Additionally, the Company stated that no consultations were held with Crowe regarding accounting principles or audit opinions prior to their appointment.
Investor Verification Checklist
- Verify the effective date of the new auditor (Crowe LLP) is July 17, 2024.
- Confirm the absence of any disagreements or reportable events with the former auditor (KMJ) as stated in the filing.
- Review the letter from KMJ Corbin & Company LLP filed as Exhibit 16.1 to ensure they concurred with the Company's statements.
- Monitor future filings for the first financial statements audited by Crowe LLP.